p53-Independent Cell Death Signaling by Mitomycin DNA Adducts
p53-Independent Cell Death Signaling by Mitomycin DNA Adducts
批准号:
7900414
负责人:
Jill E. Bargonetti
金额:
$30.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-06 至 2012-07-31
关键词:
AddressAlkylating AgentsAntibodiesAntineoplastic AgentsApoptoticAttentionAutophagocytosisBiological ModelsCaenorhabditis elegansCancer cell lineCell Culture TechniquesCell DeathCell Death Signaling ProcessCell LineCellsCessation of lifeComplexDNADNA AdductsDNA DamageDNA RepairDNA repair proteinDependencyDevelopmentDrug Delivery SystemsDrug DesignFundingGenesGeneticGenotypeGerm CellsGoalsHereditary DiseaseHomologous GeneHumanHuman Cell LineIn VitroKnock-outKnowledgeLaboratoriesLaboratory ResearchLesionLongevityMalignant NeoplasmsMediatingMeiosisMethodsMitomycinsMitoticModelingMutationNecrosisNematodaNuclear ProteinNuclear ProteinsNucleosidesOligonucleotidesOther GeneticsOutcomePathway interactionsPatientsPharmaceutical PreparationsPhenotypePhosphorylationPhosphotransferasesPlayPositioning AttributePre-Clinical ModelProtein BindingProtein p53ProteinsPublishingRNA InterferenceRecruitment ActivitySignal PathwaySignal TransductionSignal Transduction PathwaySiteStagingSystemTP53 geneTissue ModelWorkadductcancer cellcancer therapycell killingchromatin immunoprecipitationcolon cancer cell linecomparativecytotoxicitydesigndrug developmentin vivoindependencyinnovationmodel developmentmutantplasmid DNAprotein expressionpublic health relevanceresearch studysensorstereochemistrytumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The need to identify drugs and pathways that induce cell death independently of p53 deserves substantial attention. Induction of cancer cell death is challenging when p53 and other apoptotic pathways are inactivated, and requires chemotherapeutics that induce cell death pathways that do not require the tumor suppressor p53, as at least 50 percent of cancers lack a functional p53 pathway. We published that different mitomycins, which are alkylating agents, activate p53-dependent and p53-independent cell death. We see the mitomycin derivative 10-decarbamyl mitomycin C (DMC), as opposed to mitomycin C (MC), can rapidly activate a p53-independent cell death pathway which lacks markers of apoptotic death. DMC-induced cell death is a good model for identifying targets for the induction of p53-independent cell death pathways, such as necrosis and autophagy. Our central hypothesis is that DMC provokes p53-independent cell death due to specific DNA adducts formed and that elucidating the pathway(s) will enable efficient drug design parameters. Identifying the mechanisms by which DMC induces cell death is the focus of this proposal and will be a first step toward developing drugs to strategically induce cell death for the many cancers lacking functional p53 pathways. Despite the importance of p53-independent cell death, little is known about the activation of such pathways. Four aims are proposed that will use a human cancer cell line with inducible p53 and its isogenic pair (without p53) to examine p53 dependency and independency in cell death signaling, and C. elegans to serve as a preclinical model system. (1) Identify the human signal transduction pathways required for cell death in the presence and absence of p53 that are activated and/or repressed by DMC and MC. (2) Analyze the ability of DMC and MC DNA adducts in vitro and in vivo to recruit DNA repair proteins in the presence and absence of p53. (3) Perform comparative analysis of the influence of the p53 pathway and the autophagy pathway on the chemotherapeutic DNA damage-induced cell death in C. elegans and human cell systems. (4) Obtain R01 funding for my laboratory research.
There is a gap in knowledge as to how to target for p53-independent cell death. Knowledge of the signaling mechanisms for p53-independent cell death pathways will help in targeting drugs to patients who have cancers that lack functional p53.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer
-
批准号:9883911
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2020
-
负责人:Jill E. Bargonetti
-
依托单位:
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer
-
批准号:10320905
-
项目类别:
-
资助金额:$35.73万
-
财政年份:2020
-
负责人:Jill E. Bargonetti
-
依托单位:
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer
-
批准号:10545729
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2020
-
负责人:Jill E. Bargonetti
-
依托单位:
Pilot Research Project: Evaluating Black and African American Breast Cancer Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling
-
批准号:10757595
-
项目类别:
-
资助金额:$11.22万
-
财政年份:2018
-
负责人:Jill E. Bargonetti
-
依托单位:
p53-Independent Cell Death Signaling by Mitomycin DNA Adducts
-
批准号:7427239
-
项目类别:
-
资助金额:$32.9万
-
财政年份:2008
-
负责人:Jill E. Bargonetti
-
依托单位:
p53-Independent Cell Death Signaling by Mitomycin DNA Adducts
-
批准号:8113210
-
项目类别:
-
资助金额:$29.49万
-
财政年份:2008
-
负责人:Jill E. Bargonetti
-
依托单位:
p53-Independent Cell Death Signaling by Mitomycin DNA Adducts
-
批准号:7670282
-
项目类别:
-
资助金额:$32.9万
-
财政年份:2008
-
负责人:Jill E. Bargonetti
-
依托单位:
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members
-
批准号:6772180
-
项目类别:
-
资助金额:$13.7万
-
财政年份:2004
-
负责人:Jill E. Bargonetti
-
依托单位:
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE
-
批准号:6657567
-
项目类别:
-
资助金额:$3.04万
-
财政年份:2002
-
负责人:Jill E. Bargonetti
-
依托单位:
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE
-
批准号:6584182
-
项目类别:
-
资助金额:$3.04万
-
财政年份:2002
-
负责人:Jill E. Bargonetti
-
依托单位:
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE
-
批准号:6580415
-
项目类别:
-
资助金额:$3.04万
-
财政年份:2002
-
负责人:Jill E. Bargonetti
-
依托单位:
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE
-
批准号:6478856
-
项目类别:
-
资助金额:$3.04万
-
财政年份:2001
-
负责人:Jill E. Bargonetti
-
依托单位:
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE
-
批准号:6496723
-
项目类别:
-
资助金额:$3.04万
-
财政年份:2001
-
负责人:Jill E. Bargonetti
-
依托单位:
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE
-
批准号:6450683
-
项目类别:
-
资助金额:$5.95万
-
财政年份:2001
-
负责人:Jill E. Bargonetti
-
依托单位:
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE
-
批准号:6313786
-
项目类别:
-
资助金额:$5.95万
-
财政年份:2000
-
负责人:Jill E. Bargonetti
-
依托单位:
P9: WILD TYPE & MUTANT P53 INTERACTIONS W/ HIV LTR DNA: CANCER
-
批准号:6252577
-
项目类别:
-
资助金额:$10.38万
-
财政年份:1997
-
负责人:Jill E. Bargonetti
-
依托单位:
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members
-
批准号:7391697
-
项目类别:
-
资助金额:$22.0万
-
财政年份:--
-
负责人:Jill E. Bargonetti
-
依托单位:
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members
-
批准号:7219470
-
项目类别:
-
资助金额:$11.5万
-
财政年份:--
-
负责人:Jill E. Bargonetti
-
依托单位:
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members
-
批准号:7063075
-
项目类别:
-
资助金额:$11.17万
-
财政年份:--
-
负责人:Jill E. Bargonetti
-
依托单位:
WILD TYPE & MUTANT P53 INTERACTIONS WITH HIV LTR DNA
-
批准号:5224394
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Jill E. Bargonetti
-
依托单位:--
海外基金